An international randomized phase III trial of pulse actinomycin-D versus multi-day methotrexate for the treatment of low risk gestational trophoblastic neoplasia; NRG/GOG 275

Julian C. Schink, Virginia Filiaci, Helen Q. Huang, John Tidy, Matthew Winter, Jeanne Carter, Nancy Anderson, Katherine Moxley, Akira Yabuno, Sarah E. Taylor, Christina Kushnir, Neil Horowitz, David S. Miller

Research output: Contribution to journalReview article

Abstract

Objectives: Methotrexate and actinomycin-D are both effective first-line drugs for low-risk (WHO score 0–6) Gestational Trophoblastic Neoplasia (GTN) with considerable debate about which is more effective, less toxic, and better tolerated. The primary trial objective was to test if treatment with multi-day methotrexate (MTX) was inferior to pulse actinomycin-D (ACT-D). Secondary objectives included evaluation of severity and frequency of adverse events, and impact on quality of life (QOL). Methods: This was a prospective international cooperative group randomized phase III two arm non-inferiority study (Clinical Trials Identifier: (NCT01535053). The control arm was ACT-D; the experimental arm was multi-day MTX regimen (institutional preference of 5 or 8 day). Outcome measures included complete response rate, recurrence rate, toxicity, and QOL as measured by FACT-G and FACIT supplemental items. Results: The complete response rates for multi-day methotrexate and pulse actinomycin-D were 88% (23/26 patients) and 79% (22/28 patients) (p = NS) respectively, there were two recurrences in each arm, and 100% of patients survived. Significant toxicity was minimal, but mouth sores (mucositis), and eye pain were significantly more common in the MTX arm (p = 0.001 and 0.01 respectively). Quality of life showed no significant difference in overall quality of life, body image, sexual function, or treatment related side effects. The study was closed for low accrual rate (target 384, actual accrual 57), precluding statistical analysis of the primary objective. Conclusions: The complete response rate for multi-day methotrexate was higher than actinomycin-D, but did not reach statistical significance. The multi-day MTX regimens were associated with significantly more mucositis and were significantly less convenient.

Original languageEnglish (US)
JournalGynecologic oncology
DOIs
StateAccepted/In press - 2020

Keywords

  • Actinomycin-D
  • GOG
  • Gestational trophoblastic neoplasia
  • Multi-day methotrexate
  • NRG

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynecology

Fingerprint Dive into the research topics of 'An international randomized phase III trial of pulse actinomycin-D versus multi-day methotrexate for the treatment of low risk gestational trophoblastic neoplasia; NRG/GOG 275'. Together they form a unique fingerprint.

  • Cite this

    Schink, J. C., Filiaci, V., Huang, H. Q., Tidy, J., Winter, M., Carter, J., Anderson, N., Moxley, K., Yabuno, A., Taylor, S. E., Kushnir, C., Horowitz, N., & Miller, D. S. (Accepted/In press). An international randomized phase III trial of pulse actinomycin-D versus multi-day methotrexate for the treatment of low risk gestational trophoblastic neoplasia; NRG/GOG 275. Gynecologic oncology. https://doi.org/10.1016/j.ygyno.2020.05.013